With no federal drug match, the answer to "is NAD+ FDA approved" is that it is not. NAD+ prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy. It is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.
Even so, a licensed provider may still prescribe — that decision is between you and your doctor. In its compounding questions and answers, the agency states that "Compounded drugs are not FDA-approved". It also notes that "FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed".
A search of the Drugs@FDA database on October 17, 2026 returned "No matches found!" for nicotinamide adenine dinucleotide, nadide, and NAD. How a U.S. pharmacy can still prepare NAD+ comes down to Section 503A of federal law.
Not a brand drug: is NAD+ FDA approved today?
Under Section 503A, a compounding pharmacy mixes medicine for one patient on a doctor's prescription. The FDA's Section 503A bulk substances overview lists three main ways a raw ingredient can qualify. A bulk substance must comply with an applicable USP or NF monograph and the USP compounding chapter; if no applicable monograph exists, it must be a component of an approved drug; if neither condition applies, it must appear on the final 503A bulks list.
A drug monograph is a published quality standard for an ingredient's identity, strength, and purity. In the 2017 USP–NF catalog preview, the visible entry reads "Reagents, ß-Nicotinamide Adenine Dinucleotide". That public listing covers laboratory test chemicals, so it does not confirm a therapeutic drug monograph.
No current approved medicine matched NAD+ in the federal database search. The final regulation in 21 CFR § 216.23, displayed through October 15, 2026, lists six included substances and four excluded ones. Neither NAD nor NADH appears in either group.
How the May 2026 503A categories list classifies NAD+
While final rules are pending, FDA tracks nominated ingredients in its 503A bulk drug substances categories list, marked "Updated May 14, 2026". Category 1 covers "Bulk Drug Substances Under Evaluation", while Category 2 flags safety risks. Category 3 lists "Bulk Drug Substances Nominated Without Adequate Support".
| Exact entry | 503A nomination category | Interpretation |
|---|---|---|
| Nicotinamide Adenine Dinucleotide (NAD) | Category 1 | Under evaluation |
| Nicotinamide Adenine Dinucleotide Disodium Reduced (NADH) | Category 1 | Separate reduced-form entry |
| Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate | Category 3 | Nomination lacks adequate support |
Those three table rows are not interchangeable names for one ingredient. NAD+ and NADH are partner forms of a cellular coenzyme, a helper molecule that carries energy in cells. NADH is the reduced partner form, while the Category 3 row covers one specific trihydrate salt whose nomination lacked enough data.
Category 1 is a pending evaluation list rather than an approval list. Under FDA's January 7, 2025 interim policy, the agency "does not intend to take action" against Category 1 compounding when four conditions hold. As FDA's 503A overview notes, this discretion applies "provided that the conditions described in the guidance document are met".
First, the ingredient must have been nominated before January 7, 2025 with adequate support and no identified significant safety risks. Second, both the original manufacturer and every subsequent manufacturer or repackager must be establishments "registered under section 510", including foreign facilities.
Third, the raw powder must ship with a "valid COA", meaning a certificate of analysis from laboratory testing. Fourth, the finished preparation must meet "all other conditions of section 503A", including an individual prescription.
From the 2013 nomination docket to the 2017 committee vote
FDA first requested 503A bulk nominations on December 4, 2013 and reopened submissions on July 2, 2014. On October 27, 2015, a Federal Register notice opened the permanent public docket "FDA-2015-N-3534" for later nominations.
On May 8, 2017, the Pharmacy Compounding Advisory Committee reviewed NAD after a nomination for fatigue in multiple sclerosis. The September 5, 2019 proposed rule notes that NAD degrades with light, moisture, alkaline pH (low acidity), and room temperature without protection.
Reviewers also cited limited safety data for that nominated use. They wrote: "We identified no published studies that support the use of NAD for the treatment of fatigue in patients with multiple sclerosis". The committee recommended against adding NAD, and the 2019 notice proposed excluding NAD and NADH.
A proposed rule does not change federal law until it becomes final. As of October 17, 2026, the day this article was written, the September 2019 notice remains a proposed rule and NAD stays in Category 1. Meanwhile, the PCAC meeting page states that "FDA will host an advisory committee meeting before the end of February 2027" for five other substances.
The 2024 sterile-compounding alert and 2026 enforcement actions
While NAD's nomination category has not changed, regulators have stepped in when injectable products used improper raw materials. On October 30, 2024, an FDA sterile-compounding alert warned that repackagers sold food-grade NAD+ that compounders used "without appropriate processing" for IV drips. Food-grade powder is not made for injections and can carry endotoxins, which are fever-causing bacterial fragments.
The agency reported patient reactions after injectable NAD+, "including severe chills, shaking, vomiting and fatigue with some requiring medical treatment. These reactions are consistent with excessive levels of endotoxins". That phrasing notes a likely endotoxin pattern without proving contamination caused every reported case.
Recent 2026 actions also focused on facility practices. On February 9, 2026, an FDA warning letter cited sterile-processing flaws and repackaged drugs, including an NAD+ injection. Inspectors wrote that "You do not have any FDA-approved applications on file for the drug products that you repackage".
On July 27, 2026, an FDA closeout letter stated "it appears that you have adequately addressed the violations contained in this warning letter". An October 7, 2026 Bronx release reported October 6 murder charges in the NAD+ IV death, alleging catheter air caused "cardiac air embolism".
Why human studies and oral supplements do not create drug approval
Small human studies and store-bought supplement bottles do not turn an injectable compound into an approved drug. A 2019 pilot study in Frontiers in Aging Neuroscience gave eight men 750 mg of IV NAD+ over six hours. Three other men received saline, and eight-hour tracking found that "No adverse events were observed".
A 2026 retrospective study in Frontiers in Aging reviewed six clients given four daily 500 mg NAD+ infusions and eight given nicotinamide riboside. All six NAD+ clients reported "moderate to severe" cramps, nausea, vomiting, diarrhea, fast heart rate, chest pressure, congestion, and throat pain. Even so, the authors noted that "These adverse experiences ceased immediately upon infusion completion".
Our September 2026 NAD+ research update covers recent clinical papers, while oral capsules follow a separate food law. Under FDA's dietary supplement Q&A, "FDA does not have the authority to approve dietary supplements before they are marketed". By law, supplements are taken by mouth and "they must be swallowed".
A September 29, 2025 Council for Responsible Nutrition release reported that "Agency clarifies NMN is not currently precluded from supplement use". The trade group attributed that shift to earlier supplement marketing evidence, though oral supplement rules never clear an injection.
What NAD+ regulatory status means for a prescription
While final rulemaking continues, FDA describes conditional enforcement discretion for qualifying Category 1 compounding. That discretion applies subject to all four guidance conditions and the remaining Section 503A requirements.
For a patient, an accountable prescribed route identifies the reviewing provider and the licensed U.S. dispensing pharmacy. The pharmacy can be asked about the batch, its ingredient source, and its certificate of analysis. The provider and pharmacy also give the patient a contact for suspected reactions or product problems.
Human trials have not established whether morning or evening NAD+ use works better.
A prescription alone does not prove sterility. Reading questions to ask before NAD+ can help you prepare for a medical visit. At Promise, a licensed provider reviews every request and not everyone qualifies.
